- Fontanella C, Bolzonello S, Lederer B, Aprile G. Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. Breast Care. 2014;9(4):239–245. doi:10.1159/000366466.
- Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114(3):479–484. doi:10.1007/s10549-008-0018-1.
- Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer. 2010;18(5):529–541. doi:10.1007/s00520-010-0816-y.
- Amgen. Neulasta (pegfilgrastim): Full Prescribing Information. Thousand Oaks: Amgen Inc.; 2014.
- Lower EE, Charif M, Bartelt M. Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study. Cancer Chemother Pharmacol. 2018;82(1):165–170. doi: 10.1007/s00280-018-3607-7.
- Usami E, Kimura M, Iwai M, et al. The incidence and timing of leukocyte overshoot after pegfilgrastim administration. J Oncol Pharm Pract. 2018:107815521876914. [Epub ahead of print]. doi:10.1177/1078155218769140.
- Snyder RL, Stringham DJ. Pegfilgrastim-induced hyperleukocytosis. Ann Pharmacother. 2007;41(9):1524–1530.
- Lambertini M, Bruzzi P, Poggio F, et al. Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. Support Care Cancer. 2016;24(3):1285–1294. doi:10.1007/s00520-015-2907-2.
- Gong J, Wu B, Guo T, Zhou S, He B, Peng X. Hyperleukocytosis: a report of five cases and review of the literature. Oncol Lett. 2014;8(4):1825–1827.
- Donkor KN, Selim JH, Waworuntu A, Lewis K. Safety and efficacy of pegfilgrastim when given less than 14 days before the next chemotherapy cycle: review of every 14-day chemotherapy regimen containing 5-FU continuous infusion. Ann Pharmacother. 2017;51(10):840–847. doi:10.1177/1060028017714554.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 32, 2019 - Issue 2
Case Studies
Pegfilgrastim-induced hyperleukocytosis leading to hospitalization of a patient with breast cancer
Rihin ChavdaDepartment of Medicine, Texas A&M University College of Medicine, Temple, Texas; Correspondence[email protected]
http://orcid.org/0000-0003-0437-7350
, BS http://orcid.org/0000-0003-0437-7350 & Jon D. HerringtonDepartment of Pharmacy, Baylor Scott & White Medical Center–Temple, Temple, Texas; ;Department of Pharmacy, Texas A&M University College of Medicine, Temple, Texashttp://orcid.org/0000-0002-6679-3248
, PharmD, BCPS, BCOP http://orcid.org/0000-0002-6679-3248